Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Martin E Stryjewski

Showing results (11-20 of 81) with videos related to

Pageof 9
Sort By:
Infection and Drug Resistance|May 31, 2014
Clinical utility of telavancin for treatment of hospital-acquired pneumonia: focus on non-ventilator-associated pneumoniaEthan Rubinstein, Martin E Stryjewski, Steven L Barriere
Future Microbiology|March 10, 2010
Telavancin's interactions with the bacterial cell membraneEsteban C Nannini, Martin E Stryjewski, G Ralph Corey
Diagnostic Microbiology and Infectious Disease|January 14, 2015
Ceftaroline: clinical and microbiology experience with focus on methicillin-resistant Staphylococcus aureus after regulatory approval in the USAMartin E Stryjewski, Ronald N Jones, G Ralph Corey
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|January 23, 2015
Reply to DiNubileG Ralph Corey, Helen W Boucher, Martin E Stryjewski
Expert Opinion on Pharmacotherapy|April 21, 2010
Ceftaroline for complicated skin and skin-structure infectionsEsteban C Nannini, Martin E Stryjewski, G Ralph Corey
International Journal of Antimicrobial Agents|November 26, 2009
Short-course therapy for bloodstream infections in immunocompetent adultsG Ralph Corey, Martin E Stryjewski, Richard J Everts
Expert Review of Anti-Infective Therapy|October 4, 2012
Telavancin for the treatment of hospital-acquired pneumonia: findings from the ATTAIN studiesEsteban C Nannini, G Ralph Corey, Martin E Stryjewski
Expert Opinion on Pharmacotherapy|November 15, 2011
Telavancin for the treatment of serious gram-positive infections, including hospital acquired pneumoniaEthan Rubinstein, G Ralph Corey, Martin E Stryjewski, et al.
Nature Reviews. Drug Discovery|December 2, 2009
TelavancinG Ralph Corey, Martin E Stryjewski, Wim Weyenberg, et al.
Current Infectious Disease Reports|July 22, 2004
Issues in the Management of Endocarditis Caused by Resistant Gram-positive OrganismsMartin E. Stryjewski, Vivian H. Chu, Christopher H. Cabell, et al.
Pageof 9

Showing results (11-20 of 81) with videos related to

Sort By:
Pageof 9
Infection and Drug Resistance|May 31, 2014
Clinical utility of telavancin for treatment of hospital-acquired pneumonia: focus on non-ventilator-associated pneumoniaEthan Rubinstein, Martin E Stryjewski, Steven L Barriere
Future Microbiology|March 10, 2010
Telavancin's interactions with the bacterial cell membraneEsteban C Nannini, Martin E Stryjewski, G Ralph Corey
Diagnostic Microbiology and Infectious Disease|January 14, 2015
Ceftaroline: clinical and microbiology experience with focus on methicillin-resistant Staphylococcus aureus after regulatory approval in the USAMartin E Stryjewski, Ronald N Jones, G Ralph Corey
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|January 23, 2015
Reply to DiNubileG Ralph Corey, Helen W Boucher, Martin E Stryjewski
Expert Opinion on Pharmacotherapy|April 21, 2010
Ceftaroline for complicated skin and skin-structure infectionsEsteban C Nannini, Martin E Stryjewski, G Ralph Corey
International Journal of Antimicrobial Agents|November 26, 2009
Short-course therapy for bloodstream infections in immunocompetent adultsG Ralph Corey, Martin E Stryjewski, Richard J Everts
Expert Review of Anti-Infective Therapy|October 4, 2012
Telavancin for the treatment of hospital-acquired pneumonia: findings from the ATTAIN studiesEsteban C Nannini, G Ralph Corey, Martin E Stryjewski
Expert Opinion on Pharmacotherapy|November 15, 2011
Telavancin for the treatment of serious gram-positive infections, including hospital acquired pneumoniaEthan Rubinstein, G Ralph Corey, Martin E Stryjewski, et al.
Nature Reviews. Drug Discovery|December 2, 2009
TelavancinG Ralph Corey, Martin E Stryjewski, Wim Weyenberg, et al.
Current Infectious Disease Reports|July 22, 2004
Issues in the Management of Endocarditis Caused by Resistant Gram-positive OrganismsMartin E. Stryjewski, Vivian H. Chu, Christopher H. Cabell, et al.
Pageof 9